Vault CDMS to manage clinical data for trial involving
Barrett's esophagus and esophageal adenocarcinoma patients
PLEASANTON, Calif.,
May 4, 2022
/PRNewswire/ -- Veeva Systems (NYSE: VEEV) today
announced that Lucid Diagnostics Inc. (Nasdaq: LUCD), a
commercial-stage, cancer prevention medical diagnostics company,
and majority-owned subsidiary of PAVmed Inc. (Nasdaq:
PAVM, PAVMZ), has selected Veeva Vault CDMS to provide electronic
data capture (EDC), coding, and data cleaning in their upcoming
study for EsoGuard in patients undergoing standard of care
screening for, and management of, Barrett's esophagus or esophageal
adenocarcinoma.
Lucid Diagnostics is a medical device innovator developing
products to diagnose and treat conditions of the esophagus,
including those arising from chronic heartburn which may lead to
esophageal cancer. The multicenter, prospective, open-label
registry study will capture real-world data on the use of EsoGuard
testing on samples collected with EsoCheck in at-risk patients for
the detection of Barrett's esophagus and/or esophageal
adenocarcinoma.
"Every research project is unique, and we are honored that Lucid
Diagnostics chose to partner with Veeva for their critical
research," said Ami Dudzinski Mehr,
vice president of strategy, Vault CDMS, Veeva MedTech. "Veeva Vault
CDMS is designed to cope with a wide variety of study requirements
and this study is a great example of that."
Veeva is proud to support medtech companies like Lucid
Diagnostics with Vault CDMS, a unified data management solution for
today's clinical trials. Learn how Lucid Diagnostics is speeding
study builds and scaling for the future at the Veeva MedTech Summit
in Minneapolis May 31 - June 2. Industry professionals can
register here.
Additional Information
For more on Veeva Vault CDMS
for medtech, visit: veeva.com/medtech/CDMS
Connect with Veeva on LinkedIn:
linkedin.com/company/veeva-systems Follow @veevasystems on
Twitter: twitter.com/veevasystems
About Lucid Diagnostics
Lucid Diagnostics Inc.
(Nasdaq: LUCD) is a commercial-stage, cancer prevention medical
diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
Lucid is focused on the millions of patients with gastroesophageal
disease (GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device, is the
first and only commercially available diagnostic test capable of
serving as a widespread screening tool to prevent cancer and cancer
deaths through early detection of esophageal precancer in at-risk
GERD patients. EsoGuard is commercialized in the U.S. as a
Laboratory Developed Test (LDT). EsoCheck is commercialized in the
U.S. as a 510(k)-cleared esophageal cell collection device.
EsoGuard, used with EsoCheck, was granted FDA Breakthrough Device
designation and is the subject of two large, actively enrolling,
international multicenter clinical trials to support FDA PMA
approval. Lucid is building nationwide direct sales and marketing
team targeting primary care physicians, gastroenterologists, and
consumers, as well as a network of Lucid Test Centers where at-risk
GERD patients can undergo the EsoCheck procedure for EsoGuard
testing. For more information, please visit www.luciddx.com,
follow Lucid on Twitter, and connect with Lucid
on LinkedIn. For detailed information on EsoGuard, please
visit www.EsoGuard.com and follow us
on Twitter, Facebook and Instagram.
About Veeva Systems
Veeva is the global leader in
cloud software for the life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva serves
more than 1,000 customers, ranging from the world's largest
pharmaceutical companies to emerging biotechs. As a Public Benefit
Corporation, Veeva is committed to balancing the interests of all
stakeholders, including customers, employees, shareholders, and the
industries it serves. For more information, visit veeva.com.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
Shani Lewis
LaVoieHealthScience
(609) 516-5761
PAVmed@lavoiehealthscience.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-selects-veeva-vault-cdms-for-esoguard-study-301539263.html
SOURCE Veeva Systems